Track Lakefront Biotherapeutics — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lakefront Biotherapeutics LKFT.AS · Stock Open Lakefront Biotherapeutics in new tab

30.18 EUR
P/E
3.51
EPS
9.02
P/B
0.64
ROE
20.12
Beta
0.01
Target Price
31.46 EUR
Loading chart...
Key Metrics
Earnings dateNov. 11, 2026
P/E3.51
EPS9.02
Book Value49.71
Price to Book0.64
Debt/Equity0.20
% Insiders25.358%
Growth
Revenue Growth-0.82%
Estimates
Forward P/E-6.40
Forward EPS-4.95
Target Mean Price31.46

DCF valuation

Model fair value for Lakefront Biotherapeutics (LKFT.AS)
Result
Sign in to run the valuation for LKFT.AS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus None · mean target 31.46 EUR (low 19.00, high 44.80) · as of 12 Nov 2026
Low 19.00
Mean 31.46
High 44.80
Price 30.18
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Lakefront Biotherapeutics Logo Lakefront Biotherapeutics Analysis (LKFT.AS)

Belgium Healthcare Official Website Stock

Is Lakefront Biotherapeutics a good investment? Lakefront Biotherapeutics (LKFT.AS) is currently trading at 30.18 EUR. Market analysts have a consensus price target of 31.46 EUR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 3.51. This relatively low multiple may signal that Lakefront Biotherapeutics is undervalued compared to historical market norms.

Earnings Schedule: Lakefront Biotherapeutics is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -4.95.

Investor FAQ

Does Lakefront Biotherapeutics pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lakefront Biotherapeutics?

Lakefront Biotherapeutics is classified as a Stock. You can compare it against 9 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of 9.02.

Company Profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Exchange Ticker
PNK (United States) GLPGF
FRA (Germany) GXE.F
FRA (Germany) GXEA.F
AMS LKFT.AS
SAO (Brazil) G1LP34.SA
VIE (Austria) GLPG.VI
AMS (Netherlands) GLPG.AS
IOB (United Kingdom) 0JXZ.IL
GER (Germany) GXE.DE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion